When cagrilintide dosage with retatrutide questions arise: Appropriate Responses: Acknowledge that these are investigational compounds without approval for fitness applications Emphasize that no combination protocols exist in published research Redirect focus to evidence-based nutrition and training approaches that complement any medical interventions Suggest clients consult qualified medical professionals for peptide therapy decisions Provide education about realistic expectations and potential side effects Training Considerations: Clients using potent appetite suppressants like cagrilintide or retatrutide may experience: Reduced energy availability requiring modified training intensity Increased fatigue necessitating longer recovery periods Potential muscle loss if protein intake becomes inadequate Hydration challenges from GI side effects Programming should account for these factors, with emphasis on adequate nutrition, progressive overload appropriate to energy status, and careful monitoring of performance metrics
In one study, people taking tesamorelin lost about 0.9 pounds, while those on placebo had no change in body weight
Pastore, A., Federici, G., Bertini, E., & Piemonte, F
Semaglutide and tirzepatide had predecessor drugs in their same class that the FDA had already reviewed (liraglutide and native GIP, respectively)
